|
|
|
|
Neuromuscular Diseases in Geriatric Patients: Part II
Gleeson E et al.Neuromuscular disease is both common in older persons and often treatable. Neuromuscular Diseases in Geriatric Patients: Part II.
|
|
|
Amifampridine launched for rare autoimmune disease
Patients who suffer from Lambert-Eaton myasthenic syndrome (LEMS) will have a new treatment from next month (April 2010).Amifampridine (Firdapse; BioMarin Europe) tablets 10mg are due to be available in the UK on 6 April 2010 for the symptomatic treatment of...
|
|
|
Muscular Dystrophy - An NGO's Crusade to Help the Society
Medindia spoke to Dr.Vishwanathan, DCH, MRCP, Ph. D (Pediatric Neurology) Consultant Pediatric Neurologist and Founder President, Muscular Dystrophy Association India, a project that has crossed cultures and borders in research and facilities for improving...
|
|
|
Still Asleep at the (Ventilator) Switch?
Miami Beach, Fla.-Despite growing recognition that daily interruption of sedation saves lives and reduces coma as well as the duration of mechanical ventilation and time spent in the intensive care unit, the adoption of the 'wake up and breathe' protocol at...
|
|
|
Grass-roots initiative raises more than $20 million to advance MDA's lifesaving mission
The spirit of St.Patrick's Day is alive and well. The Muscular Dystrophy Association today announced that, with 92 percent of some 10,000 retail locations reporting, its 2010 Shamrocks Against Dystrophy fundraiser is the most successful in the event's 27...
|
|
|
Targeted gene therapy beneficial to mice with spinal muscular atrophy
Spinal muscular atrophy (SMA) is a neuromuscular disease characterised by progressive muscle wasting and weakness.The severity of the disease varies between individuals, with the clinical spectrum ranging from early infant death to normal adult life...
|
|
|
Drugs withdrawn from the market: Big pharma and government are not infallible
Get alerts when there is a new article from the Healthy Living Examiner.Read Examiner.com's terms of use. Email Address Include other special offers from Examiner.com Big Pharma and new drugs--moving too fast? (AP Photo/file) Every year, pharmaceutical...
|
|
|
Targeted gene therapy beneficial to mice with spinal muscular atrophy
Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive muscle wasting and weakness.The severity of the disease varies between individuals, with the clinical spectrum ranging from early infant death to normal adult life...
|
|
|
JCI online early table of contents: March 15, 2010
EDITOR'S PICK: Targeted gene therapy beneficial to mice with spinal muscular atrophy Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive muscle wasting and weakness.The severity of the disease varies between...
|
|
|
Neurological disorders in a rural Western Australian population
Background: There is limited information on the causes of neurological disorders in an Australian rural setting.Methods: This study reports on a prospective cohort of 160 patients (95 women and 65 men) with a mean age of 55.1 years (standard deviation 19.78...
|
|
|
Complete genomics finds its first diseases
Whole-genome sequencing is touted as the tech that will finally unmask our genetic "dark matter" - as-yet unknown disease-drivers that are missed by current gene scans.It hasn't done that yet, but for the first time two separate groups of researchers have...
|
|
|
Motor Neuron Synapse and Axon Defects in a C. elegans Alpha-Tubulin Mutant
Regulation of microtubule dynamics underlies many fundamental cellular mechanisms including cell division, cell motility, and transport.In neurons, microtubules play key roles in cell migration, axon outgrowth, control of axon and synapse growth, and the...
|
|
|
Avigen, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released
Refer to a friend 2010-03-10 22:49:13 - Avigen, Inc.- Pharmaceuticals & Healthcare - Deals and Alliances Profile - a new market research report on companiesandmarkets.com Avigen, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile is...
|
|
|
Santhera Pharmaceuticals Holding AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released ..
Santhera Pharmaceuticals Holding AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released Refer to a friend 2010-03-10 12:13:04 - Santhera Pharmaceuticals Holding AG - Pharmaceuticals & Healthcare - Deals and...
|
|
|
Santhera Pharmaceuticals Holding AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new
www.companiesandmarkets.com/Summary-Company-Profile/santhera-pha ..Santhera Pharmaceuticals Holding AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the...
|
|
|
Myotonic Dystrophy: Research from State University of New York, Center of Excellence in Bioinformatics has provided new information about myotonic dystrophy
Today's Medical & Research News Myotonic Dystrophy Research from State University of New York, Center of Excellence in Bioinformatics has provided new information about myotonic dystrophy March 10th, 2010 Printer-Friendly Version City:Buffalo State:NY...
|
|
|
Relationships among alexithymia and pain intensity, pain interference, and vitality in persons with neuromuscular disease: Considering the effect of negative affectivity
Hosoi M et al.Alexithymia, the inability to identify or label emotions, has been shown to be associated with pain in patients with a number of chronic pain conditions...Higher TAS (Toronto Alexithymia Scale, TAS20) scores were associated significantly with...
|
|
|
Dose-Response Relation Between Neuromuscular Electrical Stimulation and Upper-Extremity Function in Patients With Stroke
Hsu SS et al.Higher and lower doses of NMES led to similar improvements in motor function. Dose-Response Relation Between Neuromuscular Electrical Stimulation and Upper-Extremity Function in Patients With Stroke.
|
|
|
PTC Therapeutics and Genzyme Corporation Announce Preliminary Results from the Phase 2b Clinical Trial of Atal
TC Therapeutics, Inc.and Genzyme Corporation announced preliminary results from the Phase 2b clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation Duchenne/Becker Muscular Dystrophy (nmDBMD). The primary endpoint of...
|
|
|
PTC Therapeutics and Genzyme's muscular dystrophy drug ataluren fails to meet endpoint in phase-2b trial
PTC Therapeutics, Inc and Genzyme Corporation announced preliminary results from the phase-2b clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation Duchenne/Becker Muscular Dystrophy (nmDBMD).The primary endpoint of...
|
|
|
Sugammadex reverses deep block under sevoflurane
MedWire News: Sugammadex is effective for the reversal of deep neuromuscular blockade in patients under sevoflurane anesthesia, report researchers.Sevoflurane enhances the neuromuscular blocking effect of rocuronium, explain Philippe Duvaldestin ...
|
|
|
APTA Learning Center Launches Partnership With Section On Geriatricts
The American Physical Therapy Association (APTA) has partnered with its Section on Geriatrics to publish six continuing education courses to the This union reflects the first in a series of planned partnerships with APTA sections and chapters to provide quality...
|
|
|
Propofol and Other Anesthetics Remain in Short Supply
The FDA and manufacturers are struggling to keep up with demand as production problems persist.The shortage of propofol injection products that began in the second half of 2009 has become an 'ongoing and long-term problem,' FDA staff reported in a...
|
|
|
A Retrospective Review of the Sleep Characteristics in Patients with Chronic Fatigue Syndrome and Fibromyalgia
Spitzer RA et al.In these patients, who presented with neuromuscular fatigue or generalized pain, the authors found a sleep disorder characterized by objective hypersomnia. Some patients had characteristics of narcolepsy. A Retrospective Review of...
|
|
|
Targeting the Cure: A Feature Film
For Harvard Business School graduate John F.Crowley, the importance of biotechnology innovation was personal. In 1998, Crowley began fighting for his childrens lives after learning that his young son and daughter suffered from Pompe disease, a rare and...
|
